Investor Relations

Latest Financial Results

Q3 2023

Quarter Ended Sep 30, 2023

Company Overview

Developing the next generation FDA approved synthetic THC analog

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) is an early-stage life sciences company focused on the development and commercialization of MIRA1a, a synthetic analog of THC. MIRA1a is being developed to treat anxiety and cognitive decline in the elderly and neuropathic pain without impurities or the negative side effects associated with cannabis plant extracts.

Stock Snapshot

IR Contacts


MIRA Pharmaceuticals, Inc.
855 North Wolfe Street
Suite 601
Baltimore, MD 21205
United States
T: 737-289-0835

Investor Relations

MZ North America
Michael Kim / Brooks Hamilton
T: 737-289-0835

Transfer Agent

American Stock Transfer
6201 15th Ave
Brooklyn, NY 11219
T: 718-921-8124